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We investigated the kinetics of the Middle East respiratory 
syndrome coronavirus (MERS-CoV) neutralizing and spike 
protein antibody titers over the course of 1 year in 11 pa-
tients who were confirmed by reverse transcription PCR 
to have been infected during the outbreak in South Korea 
in 2015. Robust antibody responses were detected in all 
survivors who had severe disease; responses remained 
detectable, albeit with some waning, for <1 year. The dura-
tion of viral RNA detection (but not viral load) in sputum sig-
nificantly correlated with the antibody response magnitude. 
The MERS S1 ELISA antibody titers correlated well with the 
neutralizing antibody response. Antibody titers in 4 of 6 pa-
tients who had mild illness were undetectable even though 
most had evidence of pneumonia. This finding implies that 
MERS-CoV seroepidemiologic studies markedly underesti-
mate the extent of mild and asymptomatic infection. Obtain-
ing convalescent-phase plasma with high antibody titers to 
treat MERS will be challenging.
Middle East respiratory syndrome (MERS) remains a disease of global public health concern for which no 
proven specific countermeasures are available. As of De-
cember 5, 2016, ≈1,800 laboratory-confirmed cases have 
been reported (1). MERS coronavirus (MERS-CoV) is an 
enzootic pathogen present in dromedary camels in many 
parts of the world, including the Middle East, Iran, Paki-
stan, and Africa (2,3). Zoonotic infections have been re-
peatedly reported on the Arabian Peninsula and have led to 
large nosocomial outbreaks. One notable example occurred 
in South Korea in 2015, initiated by a traveler returning 
home from the Arabian Peninsula (4). The infection in this 
traveler led to an outbreak of 186 cases and 36 deaths that 
had a substantial impact on the local economy. A cohort 
of 17 patients from this outbreak was intensively followed 
up to obtain detailed clinical, immunologic, and virologic 
characterization of their disease course (5,6). The kinetics 
of the serologic responses during the acute phase have al-
ready been reported, and they showed that robust but de-
layed antibody responses could be detected in patients who 
were more severely ill (7). Another study reported a signifi-
cant linear correlation between the log
10
 viral loads and the 
serologic response in the acute phase of illness (8). The ki-
netics of the long-term serologic responses to MERS-CoV 
infections is poorly understood and remains of clinical in-
terest. We report the results of a 1-year follow-up on the 
antibody responses in 11 of these patients.
Material and Methods
Patients
The acute-phase serologic responses of a cohort of 17 pa-
tients with reverse transcription PCR (RT-PCR)–confirmed 
MERS-CoV disease admitted to Seoul National University 
(SNU) Hospital in Seoul, South Korea; SNU Boramae Medi-
cal Center in Seoul; and SNU Bundang Hospital in Seong-
nam, South Korea, were previously reported (7). Nine of 
these patients had severe disease (defined as requiring supple-
mental oxygen or mechanical ventilation). The clinical, viral 
load, and cytokine profiles were previously reported (5,6).
We followed up 11 of these patients, 5 with severe 
disease (patients C, D, F, G, and I) and 6 with mild dis-
ease (patients K, L, M, N, O, and P), for 1 year. Their se-
rum samples were collected at ≈6 months and ≈12 months 
after disease onset and used to investigate the long-term 
kinetics and duration of antibody responses that form the 
basis of this report. The clinical characteristics and early 
immunologic responses of the original and present cohorts 
of patients are summarized (online Technical Appendix 
Table 1, https://wwwnc.cdc.gov/EID/article/23/7/17-0310-
Techapp1.pdf). The reasons for the lack of follow-up for 
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the other 6 patients were transfer of care to another clinical 
unit (patient A), refusal of follow-up (patients J and Q), and 
death (patients B, E, and H). Patients B and E died during 
the acute phase of the illness, and patient H was discharged 
to receive rehabilitation care but was then given a diagnosis 
of aspiration pneumonia and died 2 months after disease 
onset. This study was approved by the Institutional Ethics 
Review Board of Seoul National University Hospital (ap-
proval no. 1506-093-681).
Viruses
The human CoV-EMC/2012 strain was used for 50% tis-
sue culture infectious dose assays, microneutralization as-
says, and plaque-reduction neutralization tests (PRNTs). 
A subset of serum samples was also tested with a strain 
from the outbreak in South Korea, MERS-CoV Hu/KOR/
SNU1_035/2015.
Serologic Tests
We heat inactivated serum samples for 30 min at 56°C 
before carrying out serologic tests. We performed the 
MERS-CoV PRNT (using a >90% plaque-reduction cut-
off [PRNT
90
]), microneutralization test, and pseudoparticle 
neutralization test (ppNT) as described (7,9) (online Tech-
nical Appendix).
We used the MERS-CoV S1 ELISA kit (EI 2604-
9601G; EUROIMMUN, Luebeck, Germany) for the de-
tection of human IgG against MERS-CoV spike protein. 
We assayed serum samples in duplicate and performed 
the assay according to the manufacturer’s instructions. 
The assay included a calibrator, which defines the upper 
limit of the reference range for noninfected humans, and 
this upper limit served as the cutoff value. The assay was 
made semiquantitative by calculating the ratio of the ex-
tinction of the patient sample over the extinction of the 
calibrator. Ratios <0.8 were considered negative, ratios 
>1.1 were considered positive, and ratios >0.8 to <1.1 
were considered borderline. We included known positive 
and negative control serum samples in all assays and de-
noted antibody titers in the reciprocal.
Statistical Analysis
We calculated peak viral loads in sputum; PRNT
90
, 
ppNT, and microneutralization antibody titers; and 
MERS S1 ELISA optical density (OD) ratios of the 11 
MERS patients by using descriptive statistics. Spear-
man correlation coefficients were calculated to cor-
relate the peak viral loads in sputum during the acute 
phase of illness with serologic responses (PRNT
90
 an-
tibody titers and MERS S1 ELISA OD ratios) at dif-
ferent times after disease onset. We also tested the 
correlation between duration of viral shedding and 
serologic responses at a 5% significance level. We 
excluded missing data from the main analyses. A sensi-
tivity analysis was performed by imputing values from 
the most recent tests.
Results
All 5 patients with severe disease, but only 2 (33%) of 
6 with mild disease (p = 0.06 by Fisher exact test), had 
PRNT
90
 antibody titers >40 at the 1-year follow-up (Figure, 
panel A). PRNT
90
 antibody titers of patients C and F, who 
had acute-phase antibody titers of >320, declined >4-fold 
1 year later. Patients D, G, K, and N who had acute phase 
peak antibody titers in the range of 80–160 only had <2-
fold declines in titer. Patients C, D, F, G, I, K, and N (the 5 
patients with severe disease and 2 of the 6 with mild disease 
who had PRNT
90
 antibody titers of >40 in their acute-phase 
serum samples [collected 21–50 days after disease onset]) 
continued to have detectable antibodies by PRNT
90
 (titer 
>1:40), ppNT (titer >1:40), microneutralization assay (titer 
>1:20), and S1 ELISA (ratio >1.1) 1 year after illness on-
set (Table; Figure, panel B). MERS antibody titers waned 
during the first 6 months after disease onset, especially in 
patients who had had high antibody titers. The waning of 
antibody titers between 6 months and 1 year after disease 
onset was less steep.
At 1 year after infection, the 4 patients who had mild 
disease (or who did not require supplemental oxygen or 
mechanical ventilation) all had negative results by micro-
neutralization assay and S1 ELISA, but 1 was positive by 
ppNT (titer of 10) and 2 by PRNT
90
 (titer 1:10) (Table). 
Although designated as having mild disease, all of these 
patients, with 1 exception (patient P), had chest infiltrates 
on x-ray, indicating lung parenchymal pathology. 
The kinetics of antibody production seen with the 
PRNT
90
, ppNT, microneutralization test, and S1 ELISA 
were comparable (Table), suggesting that any of these tests 
could be used for detection of MERS-CoV antibodies in 
patients with past infection. One year after infection, all 
patients who had antibody titers of >20 by PRNT
90
 also had 
antibodies detectable by ppNT, microneutralization assay, 
and S1 ELISA. One patient (L) with a marginal PRNT
90
 
titer of 1:10 was not positive by ppNT, microneutralization 
assay, or ELISA. At 1 year after infection, the correlation 
coefficients were 0.89 between PRNT
90
 and ppNT titers, 
0.94 between PRNT
90
 and microneutralization assay titers, 
and 0.96 between PRNT
90
 and S1 ELISA titers.
The virus we used for serologic testing was the pro-
totype MERS-CoV EMC clade A virus, and the virus that 
patients were exposed to (and that caused the outbreak in 
South Korea) was a clade B virus. To confirm that the neu-
tralizing antibody titers against the clade A and B viruses 
were not significantly different, we tested 10 paired serum 
samples (from 5 MERS-CoV patients who had various 
levels of microneutralization antibody responses to EMC) 
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by microneutralization assay using the clade A virus and a 
clade B virus from the outbreak in South Korea. The titers 
were similar (within a 2-fold dilution), confirming that the 
neutralizing epitopes of MERS-CoV are antigenically con-
served (online Technical Appendix Table 2).
The peak viral loads in sputum did not correlate 
with PRNT
90
 antibody titers or S1 ELISA OD ratios at 
the acute phase of illness, at ≈6 months after illness, or 
at ≈12 months after illness (online Technical Appendix 
Table 3). However, we found strong positive correlations 
between duration of virus detection and antibody titers (as 
measured by the PRNT
90
 and S1 ELISA) at these time 
points (online Technical Appendix Table 4). We defined 
the duration of virus detection as the day from symptom 
onset to negative PCR conversion. The median dura-
tion of virus shedding was 19 days (interquartile range 
16.5–27.5 days). Only 2 of the patients (D and F) received 
corticosteroid therapy, and both had robust antibody re-
sponses (Table). However, because of the small number 
of patients given this treatment, evaluating its quality with 
a statistical analysis was not possible.
Discussion
With this cohort of patients, we had previously reported 
that the severity of illness was associated with higher neu-
tralizing antibody responses and ELISA ODs in the acute 
phase of illness (7). The analysis of antibody titers at ≈1 
year after illness shows that these higher antibody titers 
continue to persist for at least 1 year. In the patients with 
the highest peak antibody titers, antibody titers waned 
during the first 6 months after infection but then stabilized 
over the next 6 months. This pattern of antibody produc-
tion contrasts with the pattern reported for 1 patient with 
a microneutralization titer of 400, whose titers declined 
Figure. Middle East respiratory 
syndrome (MERS) coronavirus 
antibody titers in serially 
collected serum samples 
from 11 patients with reverse 
transcription PCR–confirmed 
symptomatic MERS, South 
Korea, 2015. PRNT90 titers 
(A) and MERS spike protein 
(S1) ELISA OD ratios (B) were 
determined at multiple time 
points 0 to >400 days after 
disease onset. The limit of 
detection was 10 for the PRNT, 
and the cutoff between negative 
and borderline samples for 
the S1 ELISA was an OD ratio 
of 0.8. Letters in key indicate 
patients; red indicates those 
with severe disease, and green 
indicates those with nonsevere 
disease. OD, optical density; 
PRNT90, >90% plaque-reduction 
neutralization test.
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to an undetectable level within months by microneutral-
ization test, immunofluorescent antibody (IFA) assay, and 
ELISA (10).
Patients K, L, M, N, O, and P were designated as hav-
ing nonsevere disease because they were not given supple-
mental oxygen therapy, even though all of them, with the 
exception of patient P, had evidence of lung parenchymal 
disease. Only 2 of these patients (K and N) manifested ro-
bust antibody responses during the acute phase of the ill-
ness and early convalescence, and these titers were still 
present 1 year later. For the other patients, robust serologic 
antibody titers did not develop during the acute phase of 
the illness, and the patients remained seronegative or with 
marginal antibody titers at 1 year after infection. Because 
of the poor antibody response that resulted from symptom-
atic disease, persons with asymptomatic or mild infection 
without severe lung parenchymal disease are not expected 
to develop detectable MERS-CoV antibodies, a conclusion 
with implications for seroepidemiologic studies.
Three other studies have investigated the kinetics of 
long-term antibody persistence in patients with MERS-
CoV illness. Survivors of a MERS-CoV outbreak in Jor-
dan in April 2012 have been followed up with serologic 
testing at 13 months and 34 months after infection (11). 
These patients did not have RT-PCR–confirmed MERS-
CoV infection, but they were considered to probably have 
MERS-CoV infections because they had positive serologic 
results together with an epidemiologic link to a confirmed 
MERS patient. Seven patients had symptomatic acute up-
per respiratory disease during the outbreak; of these, 5 had 
radiologic evidence of lower lung pathology, and 2 did not 
have chest radiologic examination data. All 7 patients had 
detectable antibodies by ELISA and IFA assay, and 6 of 
them had detectable antibodies by microneutralization test 
at 13 months and 34 months after infection with titers rang-
ing from 20 to 80. However, only patients with robust sero-
logic responses were included in this study (selection bias), 
and those without were excluded by definition.
In a study in Saudi Arabia, 9 patients with RT-PCR–
confirmed MERS-CoV infection were followed up at 3 
months, 10 months, and 18 months (for only 2 patients) 
after infection and tested by MERS-CoV S1 ELISA and 
IFA assay (12). These 9 patients (2 with severe pneumo-
nia, 3 with nonsevere pneumonia, 1 with upper respira-
tory symptoms, and 3 with asymptomatic infections) were 
identified through contact tracing. All 5 patients with pneu-
monia were antibody positive by ELISA and IFA assay at 
3 months after infection, 4 were positive by ELISA at 10  
 
 
Table. Characteristics and serologic responses of patients from MERS-CoV outbreak by time after disease onset, South Korea, 2015* 
Pt. 
Severe 
disease 
Peak 
viral 
load† 
Steroid 
use 
Titers and ODs at various time points after disease onset 
PRNT90 antibody titer 
 
MERS-CoV spike 
ppNT 
 
Microneutralization 
assay titer 
 
MERS-CoV S1 
ELISA OD‡ 
21–
50 d 
180–
248 d§ 
285–403 
d§ 
21–
50 d 
180–
248 d 
285–
403 d 
21–
50 d 
180–
248 d 
285–
403 d 
21–
50 d 
180–
248 d 
285–
403 d 
C Yes 6.1 No 640 160 
(216 d) 
80 (332 d)  640 160 80  320 160 40  6.2 2.9 2.5 
D Yes 8.2 Yes  
(11–23)¶ 
160 80 
(181 d) 
80 (294 d), 
80 (397 d) 
 160 160 80  80 80 80  2.6 3.0 2.5 
F Yes 4.8 Yes  
(14–16)¶ 
320 80 
(248 d) 
80 (312 d), 
80 (403 d) 
 320 320 40  160 40 40  3.6 1.7 1.5 
G Yes 7.2 No 80 80 
(219 d) 
80 (358 d)  80 80 160  80 80 80  3.4 2.9 2.5 
I Yes 5.2 No NA# 80 
(180 d) 
80 (298 d), 
40 (370 d) 
 40 40 40  40 40 40  1.1 2.4 1.6 
K No 6.7 No 80 NA 40 (420 d)  160 NA 40  40 NA 20  1.7 NA 1.1 
L No 4.6 No <10 10 
(192 d) 
10 (285 d), 
10 (403 d) 
 10 <10 <10  <10 <10 <10  1.0 0.3 0.4 
M No 5.4 No NA** <10 
(209 d) 
<10 (296 
d), <10 
(394 d) 
 <10 <10 <10  <10 <10 <10  0 0.1 0.1 
N No 6.6 No 80 40 
(220 d) 
40 (296 d), 
40 (394 d) 
 40 80 40  80 40 20  4.1 1.6 1.4 
O No 8.2 No NA 10 
(218 d) 
10 (294 d), 
10 (379 d) 
 NA <10 10  NA <10 <10  NA 0.6 0.5 
P No 5.5 No 10 <10 
(212 d) 
<10 (290 
d), <10 
(386 d) 
 <10 <10 <10  <10 <10 <10  0.3 0.1 0.1 
*MERS-CoV, Middle East respiratory syndrome coronavirus; NA, not assayed; OD, optical density; ppNT, pseudoparticle neutralization test; PRNT90, 
>90% plaque-reduction neutralization test; Pt., patient; S1, spike protein; steroid, corticosteroid; upE, region upstream of the E gene. 
†Viral loads (log10 upE RNA copies/mL) were quantified from sputum samples. 
‡MERS-CoV S1 ELISA OD ratios <0.8 were considered negative, ≥0.8 to <1.1 were considered borderline, and ≥1.1 were considered positive. 
§Exact day(s) after disease onset that serum was collected are indicated in parentheses. 
¶Days after disease onset during which steroids were used. 
#PRNT90 antibody titer was 40 on day 18. 
**PRNT90 antibody titer was 10 on day 16. 
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months after infection, and 3 were positive by IFA assay 
at 10 months after infection. In contrast, 0 of 4 patients 
with mild upper respiratory tract infection or asymptom-
atic infection were positive by ELISA or IFA assay at 3 or 
10 months after infection. These data are comparable with 
our own, suggesting that milder infections are less likely to 
elicit serologic responses. However, that study did not pro-
vide data on virus neutralizing antibodies (12). A second 
study in Saudi Arabia reported that only 4 of 11 healthcare 
workers with real-time RT-PCR–confirmed MERS-CoV 
infection had detectable ELISA antibody titers ≈1 year af-
ter infection; of these 4 healthcare workers, 3 had detect-
able microneutralization antibody titers and only 1 had a 
high antibody titer (800) (10).
Waning antibody titers have also been demonstrated 
in patients with severe acute respiratory syndrome–CoV 
infection (13). Antibody titers peaked at 4 months after 
disease onset and declined to undetectable levels in 19% 
and 11% of serum samples by IgG test and microneutral-
ization test, respectively, 30 months after infection. Geo-
metric mean microneutralization antibody titers dropped 
from 1,232 at month 4 to 32 at month 30 after infection and 
remained at that level until month 36 (13). In volunteers ex-
perimentally infected with human CoV 229E, neutralizing 
antibody titers peaked at 3 weeks after infection and fell 
considerably by 12 weeks after infection, declining close to 
baseline levels by 1 year (14). However, human CoV 229E 
infects mainly the upper respiratory tract, unlike the patho-
gens of severe acute respiratory syndrome and MERS, 
which are more invasive of the lung parenchyma and often 
disseminate systemically.
Convalescent-phase plasma therapy has been proposed 
as a treatment option for the acute respiratory diseases, like 
MERS, that do not have specific antimicrobial treatments 
available (15,16). Our data indicate that plasma with high 
MERS-CoV antibody titers are only likely to be available 
from patients who have recovered from severe MERS dis-
ease, and these titers substantially wane within the first 6 
months of illness, although lower levels of MERS-CoV 
antibodies are maintained over longer periods. To use 
convalescent-phase patient plasma for treatment, it will be 
necessary to assess the antibody titer of potential donors 
before collection to ensure good antibody titer. A neutral-
ization test is likely to be the optimal assay for assessing 
plasma used for therapy, but because our data indicated that 
the S1 ELISA correlates well with neutralization titers, the 
S1 ELISA might be a suitable screening test for selecting 
persons for plasma donation.
One limitation of this work is the virus used for neutral-
ization tests. The clade A virus MERS-CoV EMC was used 
for assays, and the virus the patients were infected with 
and that caused the outbreak in South Korea was a clade B 
virus (the dominant virus clade currently circulating in the 
Arabian Peninsula). It has been shown that clade A and B 
viruses do not differ antigenically at the neutralization epit-
ope, although they are genetically distinct (17,18). Using a 
subset of serum samples from this study, we confirmed that 
neutralizing antibody titers obtained with the clade A EMC 
virus were similar to those obtained with a clade B virus 
strain from the outbreak in South Korea.
In conclusion, our findings support and extend the re-
search of others. We suggest that serologic tests for MERS-
CoV antibodies can only identify some of the patients who 
have had MERS-CoV infections. Serologic responses to 
this virus are variable, not robust, and often undetectable 
when disease is mild. Thus, MERS-CoV seroepidemio-
logic studies will only detect a fraction of infections that 
are occurring in a population and will probably markedly 
underestimate the extent of mild infection that is taking 
place. Our findings also show that the MERS S1 ELISA is 
as good as neutralization tests at detecting antibodies a year 
after infection, but positive ELISA results do require con-
firmation with neutralization tests if false positives are to 
be avoided in seroepidemiologic assays (M. Peiris, unpub. 
data). Convalescent-phase plasma can be harvested for 
many months to a year after disease from patients surviving 
MERS-CoV infection, but plasma with a high antibody ti-
ter is only likely to be obtained during the first few months 
of convalescence from persons who had severe disease. Be-
cause patients during this time frame are likely to be frail, 
this approach will be challenging.
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Middle East respiratory syndrome coronavirus 
(MERS-CoV) is a novel CoV known to cause 
severe acute respiratory illness in humans; 
approximately 40% of confirmed cases 
have been fatal. Human-to-human trans-
mission and multiple outbreaks of re-
spiratory illness have been attributed to 
MERS-CoV, and severe respiratory ill-
ness caused by this virus continues to be 
identified. As of February 23, 2014, the 
World Health Organization has reported 
182 laboratory-confirmed cases of MERS-
CoV infection, including 79 deaths, indi-
cating an ongoing risk for transmission to 
humans in the Arabian Peninsula.
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